scholarly journals A prospective study on the use of rivastigmine transdermal patch in Alzheimer's dementia in a routine clinical setting

2010 ◽  
Vol 4 (3) ◽  
pp. 245-249 ◽  
Author(s):  
Ejaz Nazir ◽  
Muhammad Mushtaq
Keyword(s):  
Adverse Events ◽  
Clinical Setting ◽  
Outcome Measure ◽  
Alzheimer’S Dementia ◽  
Secondary Outcome ◽  
Transdermal Patch ◽  
Alzheimer's Dementia ◽  
Rivastigmine Patch ◽  
Routine Clinical Setting ◽  
Behavioral Domains

Abstract There is not much published literature on the use of rivastigmine patch in a "routine" clinical setting. Objectives: In this naturalistic longitudinal observational study we sought to evaluate the safety, tolerability and efficacy of the rivastigmine patch in patients with early and late onset moderate Alzheimer's disease in a routine clinical setting. Methods: Out of all routine clinical referrals, the first 30 patients with diagnosis of moderate Alzheimer's dementia who were started on rivastigmine patch were included in the study. Rivastigmine patch dose was titrated from 4.6 to 9.5 mg/ 24 hours as appropriate. The primary outcome measure was safety and tolerability, measured by the incidence of adverse events and discontinuation due to any reason. The secondary outcome measure was to examine improvement on global, functional and behavioral domains as demonstrated by the MMSE (Mini Mental State Examination) score, BADLS (Bristol Activities of Daily Living Skills) score, patient and carer feedback and clinical judgment. Results: Adverse events were reported in 20% of patients and 10% of total patients needed discontinuation of treatment. Improvement on global, functional and behavioral domains was observed in two thirds of patients whereas one third showed a relative decline. The most common side effect was skin irritation or erythema. Conclusions: The rivastigmine transdermal patch may provide a treatment option for those patients who require a change in their current oral cholinesterase inhibitor therapy due to safety or tolerability concerns.

scholarly journals An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch

2011 ◽  
Vol 2011 ◽  
pp. 1-2 ◽  
Author(s):  
T. Grieco ◽  
M. Rossi ◽  
V. Faina ◽  
I. De Marco ◽  
P. Pigatto ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Side Effects ◽  
Cholinesterase Inhibitor ◽  
Alzheimer’S Dementia ◽  
Cutaneous Reaction ◽  
Transdermal Patch ◽  
Alzheimer's Dementia ◽  
Rivastigmine Patch ◽  
Cutaneous Side Effects

Rivastigmine is a cholinesterase inhibitor which improves cognitive function and is currently being used in patients with mild to moderate Parkinson's and Alzheimer's dementia. This drug can be given orally or topically, as transdermal patch. The latter form is currently used for most excellent compliance and few side effects. The most common cutaneous side effects are irritative dermatitis. We report the second case of active sensitization by the rivastigmine-patch in a patient suffering from Alzheimer's dementia.

scholarly journals ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi29-vi29
Author(s):  
Garni Barkhoudarian ◽  
Nicholas Blondin ◽  
Sajeel Chowdhary ◽  
Ekokobe Fonkem ◽  
Brian Vaillant ◽  
...  
Keyword(s):  
Adverse Events ◽  
Outcome Measure ◽  
Progression Free Survival ◽  
Primary Outcome Measure ◽  
Secondary Outcome ◽  
Secondary Outcome Measure ◽  
Newly Diagnosed ◽  
Open Label ◽  
Serious Adverse Events ◽  
Radio Frequency Energy

Abstract BACKGROUND The EMulate Therapeutics Voyager system is an investigational non-sterile, non-invasive, non-thermal, non-ionizing, portable, home-use medical device that uses a specific, localized ultra-low radio frequency energy (ulRFE®) cognate for the treatment of brain cancer. METHODS This open-label, multi-center study (NAT-109) enrolled adults newly diagnosed with GBM. Following surgical debulking, patients were enrolled and treated concurrently with temozolomide, radiotherapy, and Voyager. The objective of the study is to assess if the Voyager is a safe and feasible treatment for newly diagnosed GBM when combined with standard of care. The primary outcome measure is safety, assessed by the incidence and evaluation of any adverse events (AEs) associated with the Voyager. The secondary outcome measure is clinical utility, assessed by progression-free survival and overall survival. RESULTS Enrollment is closed, and treatment and long-term follow-up is ongoing. A total of 37 patients were enrolled and treated. 27 patients reported 282 AEs, none of which required withdrawal from the study. One AE was reported as probably related to the device - i.e., mild dysesthesia, which resolved without interruption or cessation of treatment with the device. 15 patients reported 28 SAEs, and none were reported as related to the device. 56% of patients were progression-free at 6 months, and 43% were progression-free at 12 months. 89% of patients were still alive after 6 months, 71% were still alive after 12 months. CONCLUSIONS The Voyager system appears to be safe and feasible for the treatment of newly diagnosed GBM. Given that therapy is delivered non-invasively and no device-related serious adverse events were reported, further prospective study of the investigational device is planned.

scholarly journals The CREST-E study of creatine for Huntington disease

Neurology ◽  
2017 ◽  
Vol 89 (6) ◽  
pp. 594-601 ◽  
Author(s):  
Steven M. Hersch ◽  
Giovanni Schifitto ◽  
David Oakes ◽  
Amy-Lee Bredlau ◽  
Catherine M. Meyers ◽  
...  
Keyword(s):  
Adverse Events ◽  
Huntington Disease ◽  
Primary Outcome ◽  
Outcome Measure ◽  
Functional Decline ◽  
Primary Outcome Measure ◽  
Creatine Monohydrate ◽  
Rate Of Change ◽  
Secondary Outcome ◽  
Controlled Study

Objective:To investigate whether creatine administration could slow progressive functional decline in adults with early symptoms of Huntington disease.Methods:We conducted a multicenter, randomized, double-blind, placebo-controlled study of up to 40 g daily of creatine monohydrate in participants with stage I and II HD treated for up to 48 months. The primary outcome measure was the rate of change in total functional capacity (TFC) between baseline and end of follow-up. Secondary outcome measures included changes in additional clinical scores, tolerability, and quality of life. Safety was assessed by adverse events and laboratory studies.Results:At 46 sites in North America, Australia, and New Zealand, 553 participants were randomized to creatine (275) or placebo (278). The trial was designed to enroll 650 patients, but was halted for futility after the first interim analysis. The estimated rates of decline in the primary outcome measure (TFC) were 0.82 points per year for participants on creatine, 0.70 points per year for participants on placebo, favoring placebo (nominal 95% confidence limits −0.11 to 0.35). Adverse events, mainly gastrointestinal, were significantly more common in participants on creatine. Serious adverse events, including deaths, were more frequent in the placebo group. Subgroup analysis suggested that men and women may respond differently to creatine treatment.Conclusions:Our data do not support the use of creatine treatment for delaying functional decline in early manifest HD.Clinicaltrials.gov identifier:NCT00712426.Classification of evidence:This study provides Class II evidence that for patients with early symptomatic HD, creatine monohydrate is not beneficial for slowing functional decline.

Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia

2000 ◽  
Vol 101 (4) ◽  
pp. 279-282 ◽  
Author(s):  
J. Kalman ◽  
J. Marki-Zay ◽  
A. Juhasz ◽  
A. Santha ◽  
L. Dux ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Cystatin C ◽  
Alzheimer’S Dementia ◽  
Alzheimer's Dementia
Sign in / Sign up

Export Citation Format

Share Document